These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28640700)

  • 21. Therapeutics for childhood neurofibromatosis type 1 and type 2.
    Ardern-Holmes SL; North KN
    Curr Treat Options Neurol; 2011 Dec; 13(6):529-43. PubMed ID: 21850405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain tumors in Neurofibromatosis type 1.
    Costa AA; Gutmann DH
    Neurooncol Adv; 2019; 1(1):vdz040. PubMed ID: 32642668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nosological considerations of the neurofibromatoses.
    Viskochil D; Carey JC
    J Dermatol; 1992 Nov; 19(11):873-80. PubMed ID: 1293176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurofibromatosis].
    Wolkenstein P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurofibromatosis type 2.
    Evans DG
    Handb Clin Neurol; 2015; 132():87-96. PubMed ID: 26564072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving outcomes for neurofibromatosis 1-associated brain tumors.
    Brossier NM; Gutmann DH
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibromatosis-related tumors: emerging biology and therapies.
    Karajannis MA; Ferner RE
    Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
    Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
    Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Central Nervous System Tumors.
    Kaley T; Nabors LB
    J Natl Compr Canc Netw; 2019 May; 17(5.5):579-582. PubMed ID: 31117044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hereditary tumor syndromes in neuropathology].
    Mawrin C
    Pathologe; 2017 May; 38(3):186-196. PubMed ID: 28474160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?
    Ippen FM; Colman H; van den Bent MJ; Brastianos PK
    Am Soc Clin Oncol Educ Book; 2018 May; 38():158-167. PubMed ID: 30231322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
    Kley N; Whaley J; Seizinger BR
    Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2.
    Walter J; Kuhn SA; Brodhun M; Reichart R; Kalff R
    Clin Neurol Neurosurg; 2009 Jun; 111(5):454-9. PubMed ID: 19249154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofibromatoses: part 1 - diagnosis and differential diagnosis.
    Rodrigues LO; Batista PB; Goloni-Bertollo EM; de Souza-Costa D; Eliam L; Eliam M; Cunha KS; Darrigo-Junior LG; Ferraz-Filho JR; Geller M; Gianordoli-Nascimento IF; Madeira LG; Malloy-Diniz LF; Mendes HM; de Miranda DM; Pavarino EC; Baptista-Pereira L; Rezende NA; Rodrigues Lde O; da Silva CM; de Souza JF; de Souza ML; Stangherlin A; Valadares ER; Vidigal PV
    Arq Neuropsiquiatr; 2014 Mar; 72(3):241-50. PubMed ID: 24676443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease).
    Eoli M; Bianchessi D; Di Stefano AL; Prodi E; Anghileri E; Finocchiaro G
    Neurol Sci; 2012 Dec; 33(6):1429-33. PubMed ID: 22294052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in the Classification and Treatment of Ependymomas.
    Leeper H; Felicella MM; Walbert T
    Curr Treat Options Oncol; 2017 Aug; 18(9):55. PubMed ID: 28795287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurofibromatosis.
    Roos KL; Muckway M
    Dermatol Clin; 1995 Jan; 13(1):105-11. PubMed ID: 7712636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.